REG - Hemogenyx Pharma Plc - CBR Macrophage Delivery Update

Hemogenyx PharmaceuticalsAnnouncement

06/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241206:nRSF0181Pa&default-theme=true

RNS Number : 0181P  Hemogenyx Pharmaceuticals PLC  06 December 2024

6 December 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

CBR Macrophage Delivery

 

Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates
Development

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage
biopharmaceutical company, is pleased to announce a breakthrough in its
development of a novel method for delivering Chimeric Bait Receptors ("CBR")
to innate immune cells such as macrophages and monocytes i.e. the white
myeloid blood cells that make up the body's first line of defence against
infections and responsible for the removal of diseased or damaged cells. This
innovative approach utilizes lentiviral vectors (a laboratory constructed and
modified retrovirus that can be used to insert genetic material into cells) to
achieve highly efficient transduction of macrophages or monocytes, while
maintaining durable, long-lasting CBR expression in these cells.  In more
simple terms, the new methodology will extend the efficacy as well as the
durability of CBR within transduced cells.

The Company believes that this innovative approach to myeloid immune cell
transduction will significantly accelerate the development of CBR-based
product candidates, facilitating their progression into IND-enabling studies.

 

The Company's first-class scientific team continues to make good progress with
CBR and, once sufficient resources are provided, the Company anticipates
moving new CBR-based product candidates into clinical trials, bringing them
closer to addressing unmet medical needs.

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "We are thrilled to announce this critical advancement in our CBR
platform, which represents a significant step forward in our mission to
develop cutting-edge therapies for unmet medical needs. Overcoming the
challenges of efficiently delivering CBRs to myeloid immune cells has been a
key focus for our team, and this breakthrough underscores their dedication and
ingenuity We remain committed to leveraging this technology to bring
transformative therapies to the clinic and, ultimately, to patients in need.
Once sufficient resources are available to CBR, we are confident in our
ability to translate these scientific breakthroughs into impactful
treatments."

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDTABJTMTJMBRI